Group 2 innate lymphoid cells (ILC2s) have emerged as versatile regulators in cancer immunity, exhibiting both pro-tumorigenic and anti-tumorigenic functions depending on the cytokine environment, tumor type, immune context, and ILC2 subset composition (164), This duality is rooted in their plasticity and their ability to rapidly respond to epithelial-derived alarmins such as interleukin-33 (IL-33) and interleukin-25 (IL-25). This evidence concerns the gene IL25 and cancer.